白蛋白结合型紫杉醇与顺铂联合吉西他滨治疗肺鳞状细胞癌疗效的对比研究  

Comparative study of the efficacy of albumin-binding paclitaxel vs cisplatin combined with gemcitabine in the treatment of advanced squamous cell carcinoma of the lung

作　　者：郑法德[1] 冉献贵[1] 杨瑞青[1] 齐保峰 ZHENG Fade;RAN Xiangui;YANG Ruiqing;QI Baofeng(Department of Respiratory Medicine, Fuyang People＇s Hospital, Fuyang 236000, Anhui, Chin)

机构地区：[1]阜阳市人民医院呼吸科,安徽阜阳2360000

出　　处：《癌症进展》2017年第9期1026-1028,1065,共4页Oncology Progress

摘　　要：目的比较白蛋白结合型紫杉醇与顺铂联合吉西他滨治疗晚期肺鳞状细胞癌的临床疗效。方法回顾性分析92例晚期肺鳞状细胞癌患者的临床资料,根据曾接受化疗方式的不同将患者分为观察组和对照组,每组各46例,观察组患者接受白蛋白结合型紫杉醇单药治疗,对照组患者接受顺铂联合吉西他滨治疗。比较分析两组患者的近期疗效、不良反应发生情况及生存情况,对白蛋白结合型紫杉醇治疗肺鳞状细胞癌的临床意义作出评价。结果观察组患者的有效率为17.4%,高于对照组患者的10.9%,差异无统计学意义(P﹥0.05);观察组患者的疾病控制率为71.7%,高于对照组的45.7%(P﹤0.05)。观察组患者骨髓抑制、脱发、周围神经毒性的发病率高于对照组,胃肠道反应、肾功能损害、肝功能损害的发病率低于对照组,差异无统计学意义(P﹥0.05)。观察组死亡26例,累积生存率为43.5%,中位生存时间为35个月(95%CI:32.803~37.197);对照组死亡32例,累积生存率为30.4%,中位生存时间为23个月(95%CI:16.353~29.647);观察组患者的生存情况优于对照组,差异有统计学意义(P=0.045)。结论接受白蛋白结合型紫杉醇治疗的晚期肺鳞状细胞癌患者的不良反应轻,疾病控制率高,对延长肺鳞状细胞癌患者的生存时间具有重要作用,值得临床进一步应用研究。Objective To compare the clinical efficacy of albumin-binding paclitaxel monotherapy vs cisplatin combined with gemcitabine in the treatment of advanced squamous cell carcinoma of the lung. Method The clinical data of92 patients with advanced squamous cell carcinoma of the lung were analyzed retrospectively. According to the prior chemotherapy, the patients were divided into study group and control group, with 46 cases in each. The study group received albumin-binding paclitaxel monotherapy, while the control group received combined therapy of cisplatin plus gemcitabine. The short-term efficacy, adverse events and survival of the two groups of patients were compared, and the clinical significance of albumin-binding paclitaxel in the treatment of lung squamous cell carcinoma was investigated. Result The response rate of the study group was 17.4%, which was higher than that of the control group at 10.9%, and the difference was not statistically significant（P〉0.05）; the disease control rate of the study group was 71.7%, higher than that of 45.7%in control group（P〈0.05）. The incidence of bone marrow suppression, alopecia and peripheral nerve toxicity in the study group was higher, while the incidence of gastrointestinal tract damage, renal dysfunction and liver dysfunction was lower in the study group compared to the control group, with no statistically significant difference observed（P〉0.05）. In the study group, there were 26 cases of death, with a cumulative survival rate of 43.5%, and a median survival time of 35 months（95%CI： 32.803-37.197）; while in control group, 32 cases of death were observed, with a cumulative survival rate of 30.4%, and the median survival time was 23 months（95%CI： 16.353-29.647）; the overall survival in the study group was better than that of the control group, and the difference was statistically significant（P=0.045）. Conclusion Adverse effects observed after the administration of albumin-binding paclitaxel in patients with advanced squamous cell carcinom

关 键 词：肺癌 鳞状细胞癌 化疗 白蛋白结合型紫杉醇 

分 类 号：R734.2[医药卫生—肿瘤]